期刊
ACS MEDICINAL CHEMISTRY LETTERS
卷 1, 期 5, 页码 204-208出版社
AMER CHEMICAL SOC
DOI: 10.1021/ml100051d
关键词
Cyclin-dependent kinase; oncology therapeutics; SCH 727965
Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability parameters to identify candidate CDK inhibitors with a suitable balance of activity and tolerability. This approach has resulted in the identification of SCH 727965, a potent and selective CDK inhibitor that is currently undergoing clinical evaluation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据